Phase II Trial of Hypofractionated Radiotherapy and Immunochemotherapy in Primary Refractory Diffuse Large B-Cell Lymphoma: Preliminary Results and Insights from Digital Spatial Profiling

Abstract

This open-label, single-arm phase II study assessed the safety and efficacy of sequential hypofractionated radiotherapy (RT) followed by zimberelimab and R-GemOx (rituximab, gemcitabine, oxaliplatin) in patients with primary refractory diffuse large B-cell lymphoma (DLBCL). Fourteen patients were enrolled between June 2022 and December 2023, with 13 included in the analysis. RT doses of 36 and 24 Gy were delivered to the gross and target volumes in 12 fractions, followed by zimberelimab and R-GemOx. The overall response rate within the irradiated field was 92.3%, and a complete response (CR) was achieved by 61.5% of patients; however, 38.5% experienced disease progression. Treatment-related toxicities were manageable, primarily comprising mild leukocytopenia. Digital spatial profiling revealed 53 differentially expressed genes in CD20-rich lymphoma regions and 93 in CD3-rich T cell regions in non-CR patients. Reactome analysis identified key immune system pathways. T cell infiltration correlated with treatment efficacy, and multiplex immunohistochemistry validated immune pathways as potential therapeutic targets. This study demonstrated the promising role of RT combined with immunochemotherapy in refractory DLBCL and suggests immune pathways as critical targets to improve treatment outcomes.

Keywords

diffuse large B-cell lymphoma / immune system / primary refractory / radiotherapy / zimberelimab

References

[1] L. H. Sehn and G. Salles, “Diffuse Large B-Cell Lymphoma,” New England Journal of Medicine 384, no. 9 (2021): 842-858.

[2] R. L. Siegel, A. N. Giaquinto, and A. Jemal, “Cancer Statistics, 2024,” CA: A Cancer Journal for Clinicians 74, no. 1 (2024): 12-49.

[3] B. Coiffier, E. Lepage, J. Briere, et al., “CHOP Chemotherapy Plus Rituximab Compared With CHOP Alone in Elderly Patients With Diffuse Large-B-Cell Lymphoma,” New England Journal of Medicine 346, no. 4 (2002): 235-242.

[4] M. Pfreundschuh, J. Schubert, M. Ziepert, et al., “Six Versus Eight Cycles of Bi-Weekly CHOP-14 With or Without Rituximab in Elderly Patients With Aggressive CD20+ B-Cell Lymphomas: A Randomised Controlled Trial (RICOVER-60),” The Lancet Oncology 9, no. 2 (2008): 105-116.

[5] B. Coiffier, C. Thieblemont, E. Van Den Neste, et al., “Long-Term Outcome of Patients in the LNH-98.5 Trial, the First Randomized Study Comparing Rituximab-CHOP to Standard CHOP Chemotherapy in DLBCL Patients: A Study by the Groupe d'Etudes des Lymphomes de l'Adulte,” Blood 116, no. 12 (2010): 2040-2045.

[6] J. K. Lue and O. A. O'Connor, “A Perspective on Improving the R-CHOP Regimen: From Mega-CHOP to ROBUST R-CHOP, the PHOENIX Is yet to Rise,” The Lancet Haematology 7, no. 11 (2020): e838-e850.

[7] U. Farooq, M. J. Maurer, C. A. Thompson, et al., “Clinical Heterogeneity of Diffuse Large B Cell Lymphoma Following Failure of Front-Line Immunochemotherapy,” British Journal of Haematology 179, no. 1 (2017): 50-60.

[8] M. Crump, S. S. Neelapu, U. Farooq, et al., “Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results From the International SCHOLAR-1 Study,” Blood 130, no. 16 (2017): 1800-1808.

[9] A. M. Tun, Y. Wang, S. Maliske, et al., “Autologous Stem Cell Transplant in Fit Patients With Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma That Responded to Salvage Chemotherapy,” Haematologica 109, no. 7 (2024): 2186-2195.

[10] S. S. Neelapu, F. L. Locke, N. L. Bartlett, et al., “Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma,” New England Journal of Medicine 377, no. 26 (2017): 2531-2544.

[11] F. L. Locke, D. B. Miklos, C. A. Jacobson, et al., “Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma,” New England Journal of Medicine 386, no. 7 (2021): 640-654.

[12] M. A. Lunning, H. L. Wang, Z. H. Hu, et al., “Benefit of Axicabtagene Ciloleucel Versus Chemoimmunotherapy in Older Patients and/or Patients With Poor ECOG Performance Status With Relapsed or Refractory Large B-Cell Lymphoma After 2 or More Lines of Prior Therapy,” American Journal of Hematology 99, no. 5 (2024): 880-889.

[13] O. Saifi, S. C. Lester, W. G. Breen, et al., “Incorporating Radiation With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Non-Hodgkin Lymphoma: A Multicenter Consensus Approach,” American Journal of Hematology 99, no. 1 (2024): 124-134.

[14] O. Saifi, W. G. Breen, S. C. Lester, et al., “Don't Put the CART Before the Horse: The Role of Radiation Therapy in Peri-CAR T-Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphoma,” International Journal of Radiation Oncology, Biology, Physics 116, no. 5 (2023): 999-1007.

[15] B. Zhang, M. Hu, Q. Ma, et al., “Optimized CAR-T Therapy Based on Spatiotemporal Changes and Chemotactic Mechanisms of MDSCs Induced by Hypofractionated Radiotherapy,” Molecular Therapy 31, no. 7 (2023): 2105-2119.

[16] V. M. Qin, N. M. Haynes, C. D'Souza, P. J. Neeson, and J. J. Zhu, “CAR-T Plus Radiotherapy: A Promising Combination for Immunosuppressive Tumors,” Frontiers in Immunology 12 (2021): 813832.

[17] A. Gupta, H. C. Probst, V. Vuong, et al., “Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation,” Journal of Immunology 189, no. 2 (2012): 558-566.

[18] D. Dangaj, M. Bruand, A. J. Grimm, et al., “Cooperation Between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors,” Cancer Cell 35, no. 6 (2019): 885-900.e10.

[19] A. Labani-Motlagh, M. Ashja-Mahdavi, and A. Loskog, “The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses,” Frontiers in Immunology 11 (2020): 940.

[20] C. Huang, T. L. Tang, Y. Y. Qiu, et al., “Hypofractionated Radiotherapy for Refractory or Relapsed Aggressive B-Cell Lymphoma in the Rituximab Era,” BMC Cancer 24, no. 1 (2024): 72.

[21] J. Yahalom, B. S. Dabaja, U. Ricardi, et al., “ILROG Emergency Guidelines for Radiation Therapy of Hematological Malignancies During the COVID-19 Pandemic,” Blood 135, no. 21 (2020): 1829-1832.

[22] O. Saifi, W. G. Breen, S. C. Lester, et al., “Does Bridging Radiation Therapy Affect the Pattern of Failure After CAR T-Cell Therapy in Non-Hodgkin Lymphoma?,” Radiotherapy and Oncology 166 (2021): 171-179.

[23] N. B. Figura, T. J. Robinson, A. J. Sim, et al., “Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy,” International Journal of Radiation and Oncology in Biology and Physics 111, no. 5 (2021): 1145-1154.

[24] A. Rao, D. Barkley, G. S. França, and I. Yanai, “Exploring Tissue Architecture Using Spatial Transcriptomics,” Nature 596, no. 7871 (2021): 211-220.

[25] A. A. Alizadeh, M. B. Eisen, R. E. Davis, et al., “Distinct Types of Diffuse Large B-Cell Lymphoma Identified by Gene Expression Profiling,” Nature 403, no. 6769 (2000): 503.

[26] F. Reyes, E. Lepage, G. Ganem, et al., “ACVBP Versus CHOP Plus Radiotherapy for Localized Aggressive Lymphoma,” New England Journal of Medicine 352, no. 12 (2005): 1197-1205.

[27] C. Bonnet, G. Fillet, N. Mounier, et al., “CHOP Alone Compared With CHOP Plus Radiotherapy for Localized Aggressive Lymphoma in Elderly Patients: A Study by the Groupe d'Etude des Lymphomes de l'Adulte,” Journal of Clinical Oncology 25, no. 7 (2007): 787-792.

[28] G. Held, N. Murawski, M. Ziepert, et al., “Role of Radiotherapy to Bulky Disease in Elderly Patients With Aggressive B-Cell Lymphoma,” Journal of Clinical Oncology 32, no. 11 (2014): 1112-1118.

[29] T. Lamy, G. Damaj, E. Gyan, et al., “R-CHOP With or Without Radiotherapy in Non-Bulky Limited-Stage Diffuse Large B Cell Lymphoma (DLBCL): Preliminary Results of the Prospective Randomized Phase III 02-03 Trial From the Lysa/Goelams Group,” Blood 124, no. 21 (2014): 393-393.

[30] B. S. Dabaja, A. M. Vanderplas, A. L. Crosby-Thompson, et al., “Radiation for Diffuse Large B-Cell Lymphoma in the Rituximab Era: Analysis of the N Ational C Omprehensive C Ancer N Etwork Lymphoma Outcomes Project,” Cancer 121, no. 7 (2015): 1032-1039.

[31] J. A. Vargo, B. S. Gill, G. K. Balasubramani, and S. Beriwal, “Treatment Selection and Survival Outcomes in Early-Stage Diffuse Large B-Cell Lymphoma: Do We Still Need Consolidative Radiotherapy?,” Journal of Clinical Oncology 33, no. 32 (2015): 3710-3717.

[32] A. K. Ng, J. Yahalom, J. S. Goda, et al., “Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group,” International Journal of Radiation and Oncology in Biology and Physics 100, no. 3 (2018): 652-669.

[33] V. Bucklein, A. Perez, K. Rejeski, et al., “Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-Cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use,” Hemasphere 7, no. 8 (2023): e907.

[34] N. G. Mikhaeel, M. W. Heymans, J. J. Eertink, et al., “Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index,” Journal of Clinical Oncology 40, no. 21 (2022): 2352-2360.

[35] H. Y. Yhim, Y. Eshet, U. Metser, et al., “Risk Stratification for Relapsed/Refractory Classical Hodgkin Lymphoma Integrating Pretransplant Deauville Score and Residual Metabolic Tumor Volume,” American Journal of Hematology 97, no. 5 (2022): 583-591.

[36] W. G. Breen, J. R. Young, M. A. Hathcock, et al., “Metabolic PET/CT Analysis of Aggressive Non-Hodgkin Lymphoma Prior to Axicabtagene Ciloleucel CAR-T Infusion: Predictors of Progressive Disease, Survival, and Toxicity,” Blood Cancer Journal 13, no. 1 (2023): 127.

[37] S. Yamshon, J. L. Koff, M. C. Larson, et al., “Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort Study,” American Journal of Hematology 100, no. 4 (2025): 606-615.

[38] J. S. Abramson, M. Ku, M. Hertzberg, et al., “Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) Versus Rituximab-GemOx for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (STARGLO): A Global Phase 3, Randomised, Open-Label Trial,” Lancet 404, no. 10466 (2024): 1940-1954.

[39] T. Othman, P. Frankel, P. Allen, et al., “Atezolizumab Combined With Immunogenic Salvage Chemoimmunotherapy in Patients With Transformed Diffuse Large B-Cell Lymphoma,” Haematologica 110, no. 1 (2025): 142-152.

[40] P. Ghione and G. Salles, “Spotlight on Polatuzumab Vedotin: New Standards for Diffuse Large B-Cell Lymphoma?,” Haematologica 109, no. 9 (2024): 2802-2809.

[41] M. J. Dickinson, C. Carlo-Stella, F. Morschhauser, et al., “Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma,” New England Journal of Medicine 387, no. 24 (2022): 2220-2231.

[42] P. Loap, N. Johnson, R. Birsen, J. Decroocq, and Y. Kirova, “Tolerance of Radiotherapy With Concomitant Glofitamab in Diffuse Large B Cell Lymphoma: A Case Report,” Strahlentherapie Und Onkologie 200, no. 11 (2024): 983-985.

[43] G. Marvaso, B. A. Jereczek-Fossa, M. Zaffaroni, et al., “Delphi Consensus on Stereotactic Ablative Radiotherapy for Oligometastatic and Oligoprogressive Renal Cell Carcinoma-A European Society for Radiotherapy and Oncology Study Endorsed by the European Association of Urology,” The Lancet Oncology 25, no. 5 (2024): e193-e204.

[44] N. Salim, K. Tumanova, A. Popodko, and E. Libson, “Second Chance for Cure: Stereotactic Ablative Radiotherapy in Oligometastatic Disease,” JCO Global Oncology 10 (2024): e2300275.

[45] M. F. Bassetti, B. A. Morris, N. Sethakorn, et al., “Combining Dual Checkpoint Immunotherapy With Ablative Radiation to all Sites of Oligometastatic Non-Small Cell Lung Cancer: Toxicity and Efficacy Results of a Phase 1b Trial,” International Journal of Radiation and Oncology in Biology and Physics 118, no. 5 (2024): 1481-1489.

[46] T. E. Kroese, S. Bronzwaer, P. S. N. van Rossum, et al., “European Clinical Practice Guidelines for the Definition, Diagnosis, and Treatment of Oligometastatic Esophagogastric Cancer (OMEC-4),” European Journal of Cancer 204 (2024): 114062.

[47] K. R. Tringale, H. Hubbeling, F. Chino, C. Hajj, J. Yahalom, and B. S. Imber, “Trends in Use of and Medicare Spending on Short-Course Radiotherapy for Lymphomas From 2015 to 2019,” JAMA Health Forum 3, no. 7 (2022): e221815.

[48] N. Kostopoulos, F. Costabile, E. Krimitza, et al., “Local Radiation Enhances Systemic CAR T-Cell Efficacy by Augmenting Antigen Crosspresentation and T-Cell Infiltration,” Blood Advances 8, no. 24 (2024): 6308-6320.

[49] M. Autio, S. K. Leivonen, O. Bruck, et al., “Immune Cell Constitution in the Tumor Microenvironment Predicts the Outcome in Diffuse Large B-Cell Lymphoma,” Haematologica 106, no. 3 (2021): 718-729.

[50] M. C. Zhang, S. Tian, D. Fu, et al., “Genetic Subtype-Guided Immunochemotherapy in Diffuse Large B Cell Lymphoma: The Randomized GUIDANCE-01 Trial,” Cancer Cell 41, no. 10 (2023): 1705-1716.e5.

[51] W. H. Wilson, G. W. Wright, D. W. Huang, et al., “Effect of Ibrutinib With R-CHOP Chemotherapy in Genetic Subtypes of DLBCL,” Cancer Cell 39, no. 12 (2021): 1643-1653.e3.

[52] H. W. Tsao, J. Kaminski, M. Kurachi, et al., “Batf-Mediated Epigenetic Control of Effector CD8(+) T Cell Differentiation,” Science Immunology 7, no. 68 (2022): eabi4919.

[53] Z. Y. Xu-Monette, L. Wei, X. Fang, et al., “Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-Cell Lymphoma,” Clinical Cancer Research 28, no. 5 (2022): 972-983.

[54] T. Roider, M. A. Baertsch, D. Fitzgerald, et al., “Multimodal and Spatially Resolved Profiling Identifies Distinct Patterns of T Cell Infiltration in Nodal B Cell Lymphoma Entities,” Nature Cell Biology 26, no. 3 (2024): 478-489.

[55] W. Zhao, J. Zhu, Y. Song, et al., “Tucidinostat Plus R-CHOP in Previously Untreated Diffuse Large B-Cell Lymphoma With Double Expression of MYC and BCL2: An Interim Analysis From the Phase III DEB Study,” Journal of Clinical Oncology 42, no. 17_suppl (2024): LBA7003-LBA7003.

[56] S. M. Ansell, M. C. Minnema, P. Johnson, et al., “Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study,” Journal of Clinical Oncology 37, no. 6 (2019): 481-489.

[57] Y. Gao, H. He, X. Li, et al., “Sintilimab (Anti-PD-1 Antibody) Plus Chidamide (Histone Deacetylase Inhibitor) in Relapsed or Refractory Extranodal Natural Killer T-Cell Lymphoma (SCENT): A Phase Ib/II Study,” Signal Transduction and Targeted Therapy 9, no. 1 (2024): 121.

[58] B. D. Cheson, R. I. Fisher, S. F. Barrington, et al., “Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification,” Journal of Clinical Oncology 32, no. 27 (2014): 3059-3068.

[59] Y. Yang, Y. Zhu, J. Z. Cao, et al., “Risk-Adapted Therapy for Early-Stage Extranodal Nasal-Type NK/T-Cell Lymphoma: Analysis From a Multicenter Study,” Blood 126, no. 12 (2015): 1424-1432.

[60] S. Jin, M. V. Plikus, and Q. Nie, “CellChat for Systematic Analysis of Cell-Cell Communication From Single-Cell Transcriptomics,” Nature Protocols 20, no. 1 (2025): 180-219.

[61] R. Browaeys, W. Saelens, and Y. Saeys, “NicheNet: Modeling Intercellular Communication by Linking Ligands to Target Genes,” Nature Methods 17, no. 2 (2020): 159-162.

[62] K. Rothfels, M. Milacic, L. Matthews, et al., “Using the Reactome Database,” Current Protocols 3, no. 4 (2023): e722.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.